CEO and Co-Chairman Signal Intent to Purchase Shares via Existing ATM Program

summarizeSummary

Pulse Biosciences announced that its Board approved affiliates to purchase shares through its existing ATM program, with the CEO and Co-Chairman indicating they are likely to buy shares in the near term.

check_boxKey Events

• Board Approves Affiliate Purchases via ATM

  The Board of Directors approved resolutions permitting affiliates to purchase common stock through the existing Equity Distribution Agreement (ATM program) established on February 19, 2026, without a discount to the market price.

• CEO and Co-Chairman Indicate Intent to Buy

  Mr. Robert Duggan, Co-Chairman and 72% beneficial owner, and Mr. Paul LaViolette, CEO and Co-Chairman, have indicated they are likely to purchase shares in the near term, though no binding commitments or specific amounts have been disclosed.

• Reinforces Confidence Post-Clinical Data

  This potential insider buying follows recent highly positive 12-month clinical data for the nPulse Cardiac Catheter System, reinforcing investor confidence in the company's strategic direction and product pipeline.

auto_awesomeAnalysis

This filing signals a strong vote of confidence from Pulse Biosciences' top leadership and largest shareholder. The Board's approval for affiliates to purchase shares through the existing At-The-Market (ATM) program, coupled with the explicit indication from the CEO and Co-Chairman (who also beneficially owns 72% of outstanding stock) that they are likely to buy, is a significant positive development. While the ATM program itself allows for dilution, direct insider purchases through this mechanism provide capital to the company and demonstrate conviction in its future, especially following recent positive clinical data for its nPulse Cardiac Catheter System. Investors should monitor subsequent Form 4 filings for actual purchase activity.